Morbilliform eruptions occur frequently in the hematopoietic transplant population. The differential diagnosis includes drug reaction, viral exanthem, and cutaneous graft versus host disease. Using a typical patient case, we discuss the diagnostic approach to this clinical problem.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.sder.2007.09.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prioritising gynaecological care in post-haematopoietic stem cell transplant patients.
BMJ Case Rep
January 2025
Reproductive Medicine and Surgery, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu, India.
An adolescent girl with acute myeloid leukaemia underwent chemotherapy followed by haematopoietic stem cell transplantation (HSCT). Post-HSCT, she developed oral chronic graft-versus-host disease (cGvHD), which was successfully treated. Twenty months later, she was referred to the gynaecology department for evaluation of secondary amenorrhoea.
View Article and Find Full Text PDFHow I Treat Higher-Risk MDS.
Blood
January 2025
H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
Myelodysplastic syndromes/neoplasms (MDS) are a widely heterogenous group of myeloid malignancies characterized by morphologic dysplasia, a defective hematopoiesis, and recurrent genetic abnormalities. The original and revised International Prognostic Scoring Systems (IPSS) have been used to risk-stratify patients with MDS to guide treatment strategies. In higher-risk MDS, the therapeutic approach is geared toward delaying leukemic transformation and prolonging survival.
View Article and Find Full Text PDFIn unrelated allogeneic hematopoietic cell transplantation (allo-HCT), older and/or HLA-mismatched donors are known risk factors for survival outcomes. In healthy individuals, cytomegalovirus (CMV) seropositivity is associated with impaired adaptive immune systems. We assessed whether the adverse effects of donor risk factors are influenced by the donor CMV serostatus.
View Article and Find Full Text PDFJSH practical guidelines for hematological malignancies, 2023: leukemia-6. Myelodysplastic syndromes (MDS).
Int J Hematol
January 2025
Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
The importance of targeted next-generation sequencing based genomic profiling in the diagnosis of childhood acute myeloid leukemia: a single center experience.
Turk J Pediatr
December 2024
Department of Pediatric Hematology Oncology, Ankara Bilkent City Hospital, Ankara Yıldırım Beyazıt University, Ankara, Türkiye.
Background: The management of pediatric acute myeloid leukemia (AML) is based on the prognostic risk classification of initial leukemia. Targeted next-generation sequencing (NGS) is a reliable method used to identify recurrently mutated genes of pediatric AML and associated prognosis.
Methods: In this study, we retrospectively evaluated the prognostic, and therapeutic utility of a targeted NGS panel covering twenty-five genes, in 21 children with de novo and 8 with relapsed or secondary AML.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!